盐酸巴尼地平(Barnidipine Hydrochloride) - 药物靶点：Cav2.1_在研适应症：原发性高血压，肾血管性高血压，肾实质性高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Barnidipine、Barnidipine hydrochloride (JAN)、Cyress

+ [15]

靶点

Cav2.1

作用方式

抑制剂

作用机制

Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors)

治疗领域

心血管疾病泌尿生殖系统疾病

在研适应症

原发性高血压肾血管性高血压肾实质性高血压+ [1]

非在研适应症-

原研机构

Japan Established Medicine Corp

在研机构

Japan Established Medicine Corp

LTL Pharma Co., Ltd.

Daiichi Sankyo Co., Ltd.

+ [2]

非在研机构-

权益机构

Daiichi Sankyo Co., Ltd.

Astellas Pharma, Inc.

最高研发阶段批准上市

首次获批日期

日本 (1992-01-01),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C27H30ClN3O6

InChIKeyXEMPUKIZUCIZEY-YSCHMLPRSA-N

CAS号104757-53-1

查看全部结构式(2)

关联

3

项与盐酸巴尼地平相关的临床试验

EUCTR2007-004938-16-IT

/ Not yet recruitingN/A

A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. - ND

开始日期2008-02-19

申办/合作机构

Astellas Pharma Europe BV

EUCTR2006-001469-41-IT

/ Not yet recruitingN/AIIT

Randomized, open label, multicenter ABPM study to evaluate the effects of barnidipine as add-on therapy in patients with hypertension not adequately controlled on therapy with losartan - ND

开始日期2006-08-11

申办/合作机构

Istituto Auxologico Italiano

EUCTR2005-004288-47-BE

/ Not yet recruiting临床4期IIT

Etude des effets d'un antagoniste calcique(la barnidipine) sur la sensibilité des chémorécepteurs et l'activité orthosympathique.

开始日期2005-10-04

申办/合作机构

Hôpital Erasme

100 项与盐酸巴尼地平相关的临床结果

登录后查看更多信息

100 项与盐酸巴尼地平相关的转化医学

登录后查看更多信息

100 项与盐酸巴尼地平相关的专利（医药）

登录后查看更多信息

199

项与盐酸巴尼地平相关的文献（医药）

2025-03-01·Biomedicine & Pharmacotherapy

UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists’ drugs in human plasma

Article

作者: De Rosa, Francesco Giuseppe ; Palermiti, Alice ; D'Avolio, Antonio ; Veglio, Franco ; Billi, Martina ; Fasano, Chiara ; De Nicolò, Amedeo ; Rabbia, Franco ; Manca, Alessandra ; Cusato, Jessica ; Antonucci, Miriam ; Pappaccogli, Marco ; Ponsa, Lara ; Menegatti, Giorgia ; Cantù, Marco

One of the principal challenges in managing hypertension is suboptimal medication adherence, which can result in up to 50 % of patients experiencing pseudo-resistant hypertension and inadequate blood pressure control. The intricate nature of antihypertensive regimens, the high cost of therapy, the prevalence of numerous adverse effects and the therapeutic inertia commonly lead to inconsistent drug use and premature discontinuation of treatment. Consequently, nonadherence significantly elevates the risk of cardiovascular events. Drug concentrations in the patient's serum or urine (also known as therapeutic drug monitoring, or TDM) and blood pressure measurements following supervised medication ingestion are two techniques for assessing treatment adherence. In alignment with guideline from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), this study aims to design, develop, and validate a single UHPLC method for the plasma quantification of five antihypertensive drugs within the calcium channel blocker class: amlodipine, nifedipine, barnidipine, lercanidipine and lacidipine.

2025-03-01·International Journal of Cardiology Cardiovascular Risk and Prevention

Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort

Article

作者: Galenkamp, Henrike ; Batuo, Hillman ; van der Linden, Eva ; Born, Bert-Jan van der ; Chilunga, Felix P ; Moll van Charante, Eric

BackgroundChronic inflammation is a well-recognized contributor to hypertension pathogenesis. However, the role of targeting inflammation in hypertension treatment, particularly through modulation of inflammatory markers like interleukin-6 (IL-6), remains less understood. We investigated the effects of antihypertensive medications with and without IL-6-lowering properties on long-term blood pressure (BP) control in a multi-ethnic cohort in the Netherlands.MethodsParticipants from HELIUS cohort receiving hypertension treatment were followed over six years. BP control at follow-up was determined using WHO criteria. Due to unavailability of IL-6 data, a literature review was conducted to classify antihypertensives based on their IL-6-lowering properties - a proxy approach. Logistic regression models were used to assess associations between the IL-6-lowering potential of antihypertensives and BP control, both within and between antihypertensive classes. Effect modification by ethnicity was explored.ResultsA total of 1510 participants were included (mean age 57 years, 62 % women). Within the calcium channel blocker (CCB) class, medications with IL-6-lowering properties (amlodipine and barnidipine) were associated with superior BP control (aOR 1.41, 95 % confidence interval 1.05-1.90) compared to other CCBs (lercanidipine, nifedipine, verapamil, clevidipine, diltiazem). No significant associations were observed within angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs), between different antihypertensive drug classes, nor across ethnic groups.ConclusionAmlodipine and barnidipine were associated with better BP control compared to other CCBs. Our findings provide an important starting point for understanding the role of IL-6 in hypertension management. Further studies are warranted to confirm these observations by directly measuring IL-6 levels and investigating underlying mechanisms.

2025-01-01·Clinical Rheumatology

Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study

Article

作者: Luca, Idolazzi ; Bertelle, Davide ; Mastropaolo, Francesca ; Viapiana, Ombretta ; Di Donato, Stefano ; Bixio, Riccardo ; Rossini, Maurizio ; Morciano, Andrea ; Bertoldo, Eugenia ; Adami, Giovanni ; Appoloni, Matteo

OBJECTIVESTo assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud's phenomenon (RP).METHODSWe retrospectively evaluated patients with SSc starting barnidipine 10 mg/day. Raynaud's Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up. Discontinuation rates and adverse events (AEs) were compared with retrospectively evaluated patients who started MR-nifedipine 20 mg/day at our centre.RESULTSSixty-four patients (29 barnidipine, 35 MR-nifedipine) were evaluated. Most patients starting barnidipine had a previous CCB exposure (69%; 57.9% of these were withdrawn for AEs). During follow-up, RCS decreased significantly (6.6 ± 1.8 vs 4.4 ± 1.8, p < 0.001), while the MBP did not change significantly (86.4 ± 8.4 vs 85 ± 7.3 mmHg; p = 0.36). Nine patients (31%) discontinued barnidipine during the follow-up (AEs 6/9, inefficacy 3/9). Previous CCB failure did not predict barnidipine withdrawal (OR = 0.188 95%CI [0.02-1.8]; p = 0.147). No predictors of barnidipine withdrawal were found, and no clinical or demographic differences were found between patients withdrawing and continuing barnidipine. The 6-month retention rates of barnidipine and MR-nifedipine did not differ significantly (69 vs 80%; log-rank p = 0.23), and the two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%; p = 0.48).CONCLUSIONSBarnidipine could be an effective and well-tolerated therapeutic option to treat SSc-RP, even in patients previously failing other CCBs. Key Points • Calcium channel blockers (CCBs) currently represent the first-line treatment for Raynaud's phenomenon secondary to Systemic Sclerosis (SSc-RP). However, little data exists about using novel CCBs, such as barnidipine, in this condition. • This study retrospectively evaluated patients with SSc-RP treated with barnidipine to assess its short-term efficacy. To serve as a control group for tolerability, we retrospectively compared these patients with others starting modified release-nifedipine (MR-nifedipine). • In patients treated with barnidipine, we observed a significant decrease in Raynaud's condition score at the 6-month follow-up without substantial changes in mean blood pressure. • The proportion of adverse events and drug withdrawal rate between patients starting barnidipine and MR-nifedipine did not differ significantly, even in patients starting barnidipine after previously failing other CCBs.

100 项与盐酸巴尼地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01104	盐酸巴尼地平	C08CA12	DB09227

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原发性高血压	西班牙	ADOH B.V	2000-07-11
原发性高血压	荷兰	ADOH B.V	2000-07-11
肾血管性高血压	日本	LTL Pharma Co., Ltd.	1994-09-07
肾实质性高血压	日本	LTL Pharma Co., Ltd.	1992-07-03
高血压	日本	Japan Established Medicine Corp	1992-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2024	N/A	系统性硬皮病	-	Barnidipine 10mg/day	淵觸衊繭鏇壓獵構選製(餘夢選醖淵襯蓋鑰壓築) = The two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%), the most commonly reported being headache (38.5%), hypotension (30.8%), palpitations, flushing, and edema (7.7% each). No serious AE was reported in any group. 鹹蓋襯遞鑰糧鹽範築製 (襯築糧範遞齋遞衊顧鬱 )	-	2024-06-05
				MR-nifedipine 20mg/day
[PP.35.33] (ESH2015)	N/A	2型糖尿病 \| 高血压 fasting plasma glucose \| glycated hemoglobin \| high-sensitivity C-reactive protein ... 更多	151	Barnidipine 20 mg/day + Losartan 100 mg/day	(夢積構獵鏇築壓選憲艱) = 範夢鑰鹹製鬱積選築糧齋鏇繭觸鏇觸繭憲構觸 (遞範構餘夢繭廠獵鬱廠 ) 更多	积极	2015-06-01
				Lercanidipine 20 mg/day + Losartan 100 mg/day	(夢積構獵鏇築壓選憲艱) = 築鑰齋積膚觸蓋鬱繭鏇齋鏇繭觸鏇觸繭憲構觸 (遞範構餘夢繭廠獵鬱廠 ) 更多
ASN2014	N/A	高血压 aldosterone \| renin \| cortisol ... 更多	-	Spironolactone 50mg	(網夢積鏇淵獵醖製鹽繭) = 齋衊糧選艱顧繭範繭窪窪艱淵鏇鑰鹹製廠鹽範 (憲鑰網願鹽鏇鹹願選糧, 10.8)	积极	2014-11-11
				Barnidipine 15mg	(網夢積鏇淵獵醖製鹽繭) = 鬱衊願構壓鹽觸淵鏇遞窪艱淵鏇鑰鹹製廠鹽範 (憲鑰網願鹽鏇鹹願選糧, 13.8)